MorphoSys, Immatics strike immuno-oncology pact; Versant, Weill to incubate new biotechs in NYC;

@FierceBiotech: Analysts fret as market turbulence threatens biotech IPO market. Article | Follow @FierceBiotech

@JohnCFierce: Dumped by Roche, Constellation Pharma scrambles to join IPO queue. Report | Follow @JohnCFierce

> Germany's MorphoSys AG and Immatics Biotechnologies GmbH announced a strategic alliance to generate "novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells." Release

> Versant Ventures' incubator Highline Therapeutics is partnering with Weill Cornell Medical College to spin out some new biotechs in New York City. Release

> The FDA has accepted Epizyme's ($EPZM) IND for tazemetostat, a new drug for INI1-negative tumors or synovial sarcoma. Release

Medical Device News

@FierceMedDev: ICYMI: Roche's M&A party rages on with Kapa Biosystems deal. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Bayer's Grants4Apps accelerator funds its second crop of digital health startups. Article | Follow @VarunSaxena2

@EmilyWFierce: Bristol-Myers, Sanofi catch a break in Plavix marketing case. FiercePharma story | Follow @EmilyWFierce

> WSJ: Debate roils over new radiation technique for breast cancer. More

> FDA approves first self-contained, mobile continuous blood glucose monitor from Dexcom. Article

Pharma News

@FiercePharma: India's Dr. Reddy's widens strategies to move beyond basic generics. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Mylan recalls more of the cancer meds made at Indian plants hit with FDA warning letter. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Analysts: Gilead's hep C scripts keep slowing, and Q3 sales forecasts should too. More | Follow @CarlyHFierce

> Shire rejigs manufacturing deal to step up Cinryze production. Story

> Bristol-Myers, Sanofi catch a break in Plavix marketing case. Article

> Bass failed at challenging Acorda's patents. Can pharma rest easy now? More

Drug Delivery News

> India's NIPER boasts new dry crystallization method to join growing delivery market. Article

> Benitec IPO swoons amid market rout, but other drug delivery focused players still trying to debut. More

> Former Unilife employee admits that his whistleblower suit lacked merit in legal settlement. Report

> Copper naturally assembles in bio component to make stable, scalable delivery structures. Story

> Study finds novel, rectal drug delivery catheter is useful in emergency settings. Article

Pharma Manufacturing News

> China-based biotech to build manufacturing plant in Suzhou. More

> Zoetis expands Nebraska facility even as its plots 10 plant closings. Story

> GSK expanding OTC plant that had been slated for sale. Report

> Peptide maker to triple site with $18.8M project. Article

> New compounding pharmacy company backed by Bain. Item

Pharma Asia News

> China slowdown for pharma shouldn't be ignored, WSJ says. Story

> Stem cell laws in Japan a magnet for research, Nikkei says. More

> India's Dr. Reddy's widens strategies to move beyond basic generics. Report

> Samsung Bioepis on track for $1B U.S. listing next year for biosimilar powerhouse. Story

> BeiGene plans wider footprint in China with Suzhou development site. Article

Suggested Articles

Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. Third Rock is coming, too.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.